We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PhRMA Takes Concerns About EU Transparency Plan to U.S. Trade Chief
PhRMA Takes Concerns About EU Transparency Plan to U.S. Trade Chief
PhRMA has asked the Office of the U.S. Trade Representative to put the EU on notice for its plan to publish clinical trial data that currently is treated confidentially.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor